about
Therapy for obesity based on gastrointestinal hormonesGlucagon PhysiologyEffects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesShared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial.Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative reviewImpact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity.[Gut microbiota may have influence on glucose and lipid metabolism].Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature.Use of Antibiotics and Risk of Type 2 Diabetes: A Population-Based Case-Control Study.Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptorsN-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptorTreatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake.Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetesOnce-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?Incretin hormones and beta cell function in chronic pancreatitis.Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes.The alpha-cell as target for type 2 diabetes therapy.GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies.Lixisenatide for the treatment of type 2 diabetes.Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes.Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion.Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.Glucagon and type 2 diabetes: the return of the alpha cell.Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis.GLP-1 and Amylin in the Treatment of Obesity.Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin.Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials.Clinical relevance of the bile acid receptor TGR5 in metabolism.Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide.Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery.Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review.
P50
Q27006777-ABFC5FBC-A1D1-4122-88FE-D4BAC2B18380Q27023600-763C534C-4245-43D3-A792-BF4828911E01Q27025423-85E05E53-A049-4F94-A0F7-CBEFD5C73D9CQ27333503-18AF8CFF-C0B7-48C6-AA25-7CBB6C34FFBCQ33922994-BD53DECB-2C0E-4983-9236-4BC2701F6A7AQ35062300-4F29E98D-4B85-4629-B943-EAAE6F94467CQ35120934-53FE1F17-E45B-4DF1-B1CF-97A95480952DQ35331836-2D7AFE35-7785-4DDB-930D-F0E4F8DDE22EQ35906455-8E862E95-2A30-46BE-A287-F2029D15BE57Q36129838-992C0C7F-5745-4705-B856-73EE596A5F7EQ36533318-78F48A26-7FC0-40C4-85F9-7AE860DB089EQ36599662-A199C05D-DF1D-42BD-9B35-73814B475162Q37516654-C33098EC-DF05-4047-BC1F-218235A9B66BQ37540015-FA6BD90E-BD2E-49F3-8E82-CD5E2CAE7741Q37558705-BF5238DB-2575-40B9-B24A-95650DACF228Q37631924-1E79BF54-1690-4B4B-AB06-9C219EE4906BQ37738727-2F579B9B-8B33-41D3-9C17-692255AA3CB3Q37768949-588A8084-12B0-477A-B766-20D46A944A48Q37939367-B6D474A6-9737-4962-ABEC-A00ACD6D9092Q37977335-097B7C96-3066-484B-8E0E-86C48D85CD2EQ38055195-D1552084-4A10-49F8-A85E-2F8778BEA06EQ38078816-7EEE1677-4BC1-421E-87DC-9E99E080D36FQ38148549-14B2256C-F131-4C30-A21C-70E421F96C97Q38195530-D57B2018-8B19-4FF6-B1CC-28A863E2C170Q38201586-29865730-C733-4078-9CFA-7BB479E8A0A0Q38206744-CB583B47-4C75-431D-B4B2-F43BB6259B93Q38231646-FA7D1323-310E-4103-A901-45434EE6BC18Q38239573-796546EC-2E4E-44C4-833E-4A2D8EEED2ABQ38262673-9C49C443-A7BD-4485-88E0-8813FC7006FDQ38625348-9F566340-10AB-4AA1-8519-CD39A982431EQ38677851-C5647562-D3BC-41DF-9781-12BD8B848F11Q38830154-5BA38BBE-F66C-4C57-9FE6-1C10108FA811Q38855893-5B26C6BF-B9C5-40F8-87DF-CB9CB3EA9B08Q38941425-01721A76-6465-4236-9CBC-A3A3F62ACFE0Q38957548-F7EE3881-55A3-45F9-ACB4-5DA0152C1FEDQ39041615-3B5E53C8-3F7E-4F7A-A7D8-C6E713AB26E6Q39077488-A98E426D-60DA-4275-8CD9-D3CF8CA8A826Q39096167-C1912720-464E-4DC9-9941-49C42000D35DQ39140474-C899C87E-855C-4998-A879-826D7CB0C453Q39183556-5267F946-91C6-47D5-9F18-0F6D7E61A92D
P50
description
researcher ORCID ID = 0000-0002-2495-5034
@en
wetenschapper
@nl
name
Filip K Knop
@ast
Filip K Knop
@en
Filip K Knop
@nl
type
label
Filip K Knop
@ast
Filip K Knop
@en
Filip K Knop
@nl
prefLabel
Filip K Knop
@ast
Filip K Knop
@en
Filip K Knop
@nl
P106
P31
P496
0000-0002-2495-5034